URGN Insider Trading

UroGen Pharma Ltd. (URGN) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.28B, listed on NASDAQ, employing roughly 300 people, carrying a beta of 1.64 to the broader market. UroGen Pharma Ltd. Led by Elizabeth Barrett, public since 2017-05-04.

In the last 12 months, UroGen Pharma Ltd. insiders made 0 buy transactions and 15 sale transactions.

DateNameTypeSharesPriceValue
Oct 9, 2026Degnan ChrisM-Exempt4,483$0.00$0
Oct 9, 2026Degnan ChrisS-Sale2,202$36.69$80.8K
Oct 9, 2026Degnan ChrisM-Exempt4,483$0.00$0
Sep 9, 2026Schoenberg MarkM-Exempt1,667$0.00$0
Sep 9, 2026Schoenberg MarkS-Sale871$42.92$37.4K
Sep 9, 2026Schoenberg MarkM-Exempt1,667$0.00$0
Sep 9, 2026Smith Jason DrewM-Exempt3,334$0.00$0
Sep 9, 2026Smith Jason DrewS-Sale1,519$42.54$64.6K
Sep 9, 2026Smith Jason DrewM-Exempt3,334$0.00$0
Aug 28, 2026Robinson James A. Jr.M-Exempt2,000$0.00$0

URGN Insider Activity by Quarter

Reported Form 4 and Form 5 lines under URGN's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Aug 22, 2019, and a quarter counts only when every filing for it was read. Last refreshed Nov 2, 2026.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A1$80.8K2
Q3 20260N/A4$3.4M6
Q2 20260N/A3$792.7K14
Q1 20260N/A6$292.4K16
Q4 20250N/A2$287.1K12
Q3 20250N/A5$465.1K18
Q2 20250N/A1$38.0K2
Q1 20250N/A6$132.9K17
Q4 20240N/A0N/A2

URGN Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 189 institutions reported holding 42,423,863 URGN shares, valued at $1.56B as reported, 90.0% of its market cap (market cap of Jun 26, 2026). That is +16 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 39 opened a position, 17 closed one, 61 added and 54 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
RTW INVESTMENTS, LP4,543,895$167.2MUnchanged
BlackRock, Inc.3,201,461$117.8M+355,894
MORGAN STANLEY2,576,363$94.8M+16,325
Kynam Capital Management, LP2,434,207$89.6M+186,814
Jefferies Financial Group Inc.2,199,652$80.9MUnchanged
SG Americas Securities, LLC2,052,906$75.5M+395,060
AMERICAN CENTURY COMPANIES INC1,685,719$62.0M+48,149
ACORN CAPITAL ADVISORS, LLC1,673,420$61.6MUnchanged
Point72 Asset Management, L.P.1,525,549$56.1MNew
FRONTIER CAPITAL MANAGEMENT CO LLC1,508,547$55.5M+194,435

By Quarter

QuarterInstitutionsSharesValue
Q2 202618942,423,863$1.56B
Q1 202617346,442,210$835.2M
Q4 202516743,721,890$1.02B
Q3 202516144,509,979$887.9M
Q2 202514940,662,775$557.0M
Q1 202514041,654,130$460.7M
Q4 202413836,274,940$386.3M
Q3 202412835,196,496$446.6M
Q2 202411540,083,001$672.6M

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding URGN

FundWeight of URGNShares (as reported)Value (as reported)Source updated
SPDW State Street SPDR Portfolio Developed World ex-US ETF0.01%194,821$5.1MNov 12, 2026
IZRL ARK Israel Innovative Technology ETF1.46%65,657$1.7MNov 13, 2026
CANC Tema Oncology ETF0.68%55,010$1.5MNov 13, 2026
SEIS SEI Exchange Traded Funds - SEI Select Small Cap ETF0.09%21,123$557.4KNov 13, 2026
AFSM First Trust Active Factor Small Cap ETF0.18%9,691$252.9KNov 12, 2026
ACSG American Century Small Cap Growth Insights ETF0.30%6,197$161.7KNov 13, 2026
IBBQ Invesco Nasdaq Biotechnology ETF0.08%4,012$104.7KNov 12, 2026
AVTM Avantis Total Equity Markets ETF 10.01%3,304$86.2KNov 13, 2026
RFLR Innovator U.S. Small Cap Managed Floor ETF0.04%1,403$37.0KNov 13, 2026
AVUQ Avantis U.S. Quality ETF0.00%238$6.2KNov 13, 2026
KBFR Innovator U.S. Small Cap Managed 10 Buffer ETF0.05%231$6.1KNov 13, 2026
IQES Invesco U.S. Small Cap Enhanced ETF0.04%90$2.3KNov 12, 2026

From each fund's latest holdings file on record that shows URGN's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as URGN's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for URGN reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is URGN's share of that fund.

How to Read URGN Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 15 sales versus 0 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked URGN insider trading questions

How active are URGN insiders right now?
Over the trailing twelve months, UroGen Pharma Ltd. (URGN) insiders made 0 buy transactions and 15 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (15 sales vs 0 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are URGN insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do URGN insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.